VYD2311

BIOLOGICAL2 trials

Sponsors

Invivyd, Inc.

Conditions

COVID-19

Phase 1

A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants

Active, not recruitingNCT06523153

Invivyd, Inc.COVID-19

Start: 2024-08-28End: 2025-05-31Target: 40Updated: 2024-11-19

Phase 3

Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine

RecruitingNCT07655180

Invivyd, Inc.COVID-19

Start: 2026-06-08End: 2026-08-01Target: 210Updated: 2026-06-17